Clinical Trials
8 trialsNCT06756035 2026-06-04
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Phase 1 Recruiting
NCT00242723 2026-06-03
Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
National Institutes of Health Clinical Center (CC)
Recruiting
NCT04981119 2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
NCT06477419 2026-05-28
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT03007030 2026-05-15
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05568680 2026-05-12
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
Phase 1 Recruiting
NCT06251310 2026-05-08
SW-682 in Advanced Solid Tumors
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Recruiting